Cyclacel : study of seliciclib synergy with Tarceva and Herceptin in journal Clinical Cancer Research

July 14, 2008 – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced the publication of a study conducted by Cyclacel scientists showing synergistic activity between its investigational therapy seliciclib and multiple epidermal growth factor receptor (EGFR) inhibitors, including erlotinib (Tarceva®) in models of non-small cell lung cancer and the HER2 targeting agent, trastuzumab (Herceptin®) in models of breast cancer. These preclinical results were published in the July issue of the journal, Clinical Cancer Research. Seliciclib, Cyclacel’s orally available cyclin dependent kinase (CDK) inhibitor, is currently being tested as a single agent in the Phase 2b APPRAISE trial in patients with non-small cell lung cancer and in a Phase 2 study in patients with nasopharyngeal cancer... Cyclacel's Press Release -

Vall d’Hebron University Hospital and Cyclacel Pharmaceuticals to initiate Phase 1 combination study of Seliciclib and Tarceva

May 29, 2008 – Vall d’Hebron University Hospital and Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced a collaboration to conduct a Phase 1 study of investigational therapy seliciclib in combination with erlotinib (Tarceva®) in patients with advanced solid tumors including non-small cell lung cancer (NSCLC). Seliciclib, Cyclacel’s orally available cyclin dependent kinase (CDK) inhibitor, has shown encouraging anti-cancer activity in several Phase 1 and Phase 2 studies. Seliciclib is currently being tested as a single agent in the treatment of patients with non-small cell lung cancer in the Phase 2b APPRAISE trial and in a Phase 2 study in patients with nasopharyngeal cancer... Cyclacel Pharmaceuticals' Press Release -